Adrenocortical Carcinoma clinical trials

Explore recruiting adrenocortical carcinoma clinical trials.

Recruiting adrenocortical carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Adrenocortical Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Adjuvant mitotane vs. mitotane with cisplatin/etoposide after primary surgical resection of localised adrenocortical carcinoma with high risk of recurrence (ADIUVO-2 Trial): A pragmatic, randomised, low-intervention phase III, clinical trial with an observational arm.

Germany, Sweden, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

PROSPECTIVE, PHASE II STUDY TO EVALUATE THE EFFICACY OF ADDITION OF PROGESTERONE TO STANDARD CHEMOTHERAPY ACCORDING TO EDP SCHEME PLUS MITOTANE IN PATIENTS WITH ADVANCED ADRENAL CORTICAL CARCINOMA - PESETA TRIAL

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Cemiplimab maintenance treatment for advanced adrenocortical cancer

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A multicentre, open-label phase 2 study to evaluate the efficacy and safety of pembrolizumab in the treatment of advanced, progressive adrenocortical carcinoma

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A first-in-human clinical study to assess safety and tolerability of genetically modified T-cells in ROR1 positive tumors

Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

First-in-Human trial of DS9051b in participants with advanced solid tumors

France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Adrenocortical Carcinoma trials by city

Adrenocortical Carcinoma clinical trials

Recruiting adrenocortical carcinoma studies right now

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors

Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma

Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)

Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma

Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.

Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcinoma

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

Also recruiting in Europe

Adjuvant mitotane vs. mitotane with cisplatin/etoposide after primary surgical resection of localised adrenocortical carcinoma with high risk of recurrence (ADIUVO-2 Trial): A pragmatic, randomised, low-intervention phase III, clinical trial with an observational arm.

PROSPECTIVE, PHASE II STUDY TO EVALUATE THE EFFICACY OF ADDITION OF PROGESTERONE TO STANDARD CHEMOTHERAPY ACCORDING TO EDP SCHEME PLUS MITOTANE IN PATIENTS WITH ADVANCED ADRENAL CORTICAL CARCINOMA - PESETA TRIAL

Cemiplimab maintenance treatment for advanced adrenocortical cancer

A multicentre, open-label phase 2 study to evaluate the efficacy and safety of pembrolizumab in the treatment of advanced, progressive adrenocortical carcinoma

A first-in-human clinical study to assess safety and tolerability of genetically modified T-cells in ROR1 positive tumors

First-in-Human trial of DS9051b in participants with advanced solid tumors

Adrenocortical Carcinoma trials by city

Other conditions